Corporate Update: Betterlife Pharma (BETR.CN)
Market Snapshot
Trading Performance (24 h ending 11:51 PM CET, Thu 22 Oct 2026)
Up 25 % to CAD 0.25 per share on major exchanges.
Trading volume: CAD 508.2 k worth of shares moved in the last 24 hours.
Supply & Capitalisation
Shares outstanding: 618 million.
Market capitalisation: CAD 148.3 million.
Trend Context
Year‑to‑date: –21.88 % relative to the previous month‑end.
200‑day simple moving average (SMA): CAD 0.15.
52‑week high: CAD 0.46 (08 Jul 2026).
52‑week low: CAD 0.04 (01 Jul 2026).
Peer Activity (Past 24 h)
| Ticker | Change | Price (CAD) | Market Cap (CAD mn) | Notes |
|---|---|---|---|---|
| FEO.V (Oceanic Iron Ore) | +4.84 % | 0.61 | 170 | Solid rebound |
| NURS.V (Hydreight) | +1.24 % | 3.13 | 172.8 | Incremental upside |
| TINY.TO (Tiny) | 0 % | 6.25 | 177.3 | Flat |
| KLD.V (Kenorland Minerals) | –1.39 % | 2.10 | 173.9 | Mild decline |
| LGC.V (Lavras Gold) | –0.36 % | 2.63 | 174.3 | Slight dip; strategic drilling update |
Lavras Gold Highlights
Lavras Gold Corp. announced the approval of a fourth diamond drill rig to target the Cerrito North area within its Lavras do Sul project in Brazil. The program will drill approximately 2,000 m across 22 holes at 70‑150 m depths, aiming to confirm whether surface gold‑in‑soil anomalies correspond to mineralised bedrock. The company remains on schedule to submit its Fazenda‑Butia licence‑permit application by December 2026, following an environmental authority extension. The announcement underscores an integrated targeting approach combining geochemical, geophysical, and spectral data to evaluate early‑stage gold potential.
Company Overview
Betterlife Pharma Inc. is a Canadian development‑stage pharmaceutical and nutraceutical company. It focuses on the creation and commercialization of therapeutic agents and nutraceuticals, leveraging proprietary drug‑delivery platform technologies to enhance efficacy and patient outcomes.
Forward‑Looking Perspective
The recent 25 % surge in Betterlife Pharma’s share price reflects a renewed confidence among market participants, likely driven by perceived progress in its pipeline and the company’s strategic positioning within the nutraceutical sector. While the –21.88 % YTD decline underscores volatility typical of early‑stage biopharma, the 200‑day SMA at CAD 0.15 suggests a solid support level that the current trading range is well above. Should the company advance clinical milestones or secure strategic partnerships, further upside could materialise, potentially approaching the 52‑week high of CAD 0.46.
In the broader context, peer performance indicates a modestly bullish environment for resource‑focused stocks, with Oceanic Iron Ore and Hydreight showing positive moves. The slight dip in Lavras Gold, despite its drilling expansion, highlights the nuanced dynamics of commodity exploration versus biotech development.
Investors and stakeholders should monitor upcoming regulatory filings, clinical data releases, and partnership announcements, as these will be pivotal in determining whether the current momentum sustains or reverses.
This report is intended for informational purposes only and does not constitute investment advice.